Efbemalenograstim alfa

From WikiProjectMed
Jump to navigation Jump to search

Efbemalenograstim alfa
Clinical data
Trade namesRyzneuta
Other namesF-627, efbemalenograstim alfa-vuxw, benegrastim
AHFS/Drugs.comMonograph
MedlinePlusa624001
License data
Routes of
administration		Subcutaneous
Drug classImmunological agent
ATC code
Legal status
Legal status
Identifiers
CAS Number
UNII
KEGG

Efbemalenograstim alfa, sold under the brand name Ryzneuta, is a medication used to decrease the incidence of infection in chemotherapy-induced neutropenia.[1] It is a leukocyte growth factor.[1] It is given by subcutaneous injection.[1]

The most common side effects of efbemalenograstim alfa are nausea, anemia, and thrombocytopenia.[5]

Efbemalenograstim alfa is an immunostimulant/colony stimulating factor that belongs to the class of hematopoietic growth factors (granulocyte colony stimulating factor; G CSF) which increase the production and differentiation of mature and functionally active neutrophils from bone marrow precursor cells.[2] It was approved for medical use in China in May 2023,[4] in the United States in November 2023,[5][6] and in the European Union in March 2024.[2][3]

Medical uses

In the US, efbemalenograstim alfa is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adults with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.[1][5]

In the EU, efbemalenograstim alfa is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adults treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).[2]

Side effects

Efbemalenograstim alfa can cause fatal splenic rupture, acute respiratory distress syndrome, serious allergic reactions including anaphylaxis, sickle cell crises in patients with sickle cell disorders, glomerulonephritis, thrombocytopenia, capillary leak syndrome, and myelodysplastic syndrome and acute myeloid leukemia in people with breast and lung cancer.[5]

History

The US Food and Drug Administration approved efbemalenograstim alfa based on evidence from two main clinical trials, GC-627-04 and GC-627-05, in 515 participants with breast cancer receiving chemotherapy.[5] There was one participant included in the trial from the United States, and 514 participants were included from sites outside of the United States.[5] The trials were conducted at 52 sites in five countries including Hungary, Russia, Ukraine, Bulgaria, and the United States.[5] The same trials (GC-627-04 and GC-627-05) were used to assess efficacy and safety.[5]

Efbemalenograstim alfa was evaluated in two main clinical trials that were randomized and controlled.[5] A total of 515 participants were randomized to receive efbemalenograstim alfa or placebo, or Neulasta, after receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia to treat metastatic breast cancer.[5] Both trials evaluated the benefit and side effects of efbemalenograstim alfa in participants.[5] The benefit of efbemalenograstim alfa was based on the mean duration of severe neutropenia seen in participants after receiving either efbemalenograstim alfa or control (placebo or Neulasta).[5]

Society and culture

Legal status

It was approved for medical use in China in May 2023,[4] in the United States in November 2023,[1][5] and in the European Union in March 2024.[3]

In January 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Ryzneuta, intended to reduce the duration of neutropenia and the incidence of febrile neutropenia due to chemotherapy.[2] The applicant for this medicinal product is Evive Biotechnology Ireland Limited.[2] Efbemalenograstim alfa was approved for medical use in the European Union in March 2024.[2][3]

References

  1. ^ a b c d e f "Ryzneuta- efbemalenograstim alfa-vuxw injection". DailyMed. 23 November 2023. Archived from the original on 12 December 2023. Retrieved 12 December 2023.
  2. ^ a b c d e f g "Ryzneuta EPAR". European Medicines Agency (EMA). 25 January 2024. Archived from the original on 29 January 2024. Retrieved 3 February 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  3. ^ a b c d "Ryzneuta Product information". Union Register of medicinal products. 22 March 2024. Archived from the original on 26 March 2024. Retrieved 1 April 2024.
  4. ^ a b c Blair HA (August 2023). "Efbemalenograstim Alfa: First Approval". Drugs. 83 (12): 1125–1130. doi:10.1007/s40265-023-01911-7. PMID 37368138. S2CID 259260831. Archived from the original on 20 November 2023. Retrieved 18 November 2023.
  5. ^ a b c d e f g h i j k l m "Drug Trials Snapshots: Ryzneuta". U.S. Food and Drug Administration (FDA). 16 November 2023. Archived from the original on 6 May 2024. Retrieved 6 May 2024. Public Domain This article incorporates text from this source, which is in the public domain.
  6. ^ "Novel Drug Approvals for 2023". U.S. Food and Drug Administration (FDA). 17 November 2023. Archived from the original on 21 January 2023. Retrieved 20 November 2023.

External links


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://mdwiki.org/wiki/Efbemalenograstim_alfa"